We are live on
!
Find out more
TD Asset Management Portfolio holdings
AUM
$115B
1-Year Est. Return
41.58%
This Fund
S&P 500
This Quarter
Est. Return
+4.86%
1 Year Est. Return
+41.58%
3 Year Est. Return
+119.77%
5 Year Est. Return
+143.7%
10 Year Est. Return
+463.95%
AUM
$124B
AUM Growth
+$1.17B
(+0.95%)
Cap. Flow
-$2.52B
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
27.63%
Holding
1,313
New
78
Increased
555
Reduced
547
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amphenol
APH
|
+$281M |
| 2 |
Eli Lilly
LLY
|
+$265M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$230M |
| 4 |
Apple
AAPL
|
+$211M |
| 5 |
Cencora
COR
|
+$194M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$626M |
| 2 |
Meta Platforms (Facebook)
META
|
+$409M |
| 3 |
Republic Services
RSG
|
+$224M |
| 4 |
Motorola Solutions
MSI
|
+$206M |
| 5 |
Oracle
ORCL
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.37% |
| 2 | Technology | 22.54% |
| 3 | Industrials | 9.15% |
| 4 | Healthcare | 8.46% |
| 5 | Consumer Discretionary | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Surgery Partners
SGRY
$1.99B
| $250K | ﹤0.01% |
16,180
-3,672
| -18% | -$67.5K |
|
1202
Essent Group
ESNT
$6.23B
| $241K | ﹤0.01% |
+3,700
| New | +$230K |
|
1203
Annexon
ANNX
$862M
| $235K | ﹤0.01% |
46,848
| – | – |
|
1204
Janux Therapeutics
JANX
$978M
| $235K | ﹤0.01% |
17,006
-75,296
| -82% | -$1.77M |
|
1205
Equinor
EQNR
$96.3B
| $229K | ﹤0.01% |
9,711
+501
| +5% | +$11.8K |
|
1206
Symbotic
SYM
$5.43B
| $223K | ﹤0.01% |
3,753
-101
| -3% | -$6.67K |
|
1207
iShares MSCI USA Min Vol Factor ETF
USMV
$24.6B
| $222K | ﹤0.01% |
2,354
+172
| +8% | +$16.2K |
|
1208
Aura Biosciences
AURA
$791M
| $221K | ﹤0.01% |
40,502
-28,528
| -41% | -$169K |
|
1209
Landstar System
LSTR
$6.4B
| $216K | ﹤0.01% |
1,500
-8,600
| -85% | -$1.15M |
|
|
NESR
1210
National Energy Services Reunited Corp
NESR
$3.62B
| $215K | ﹤0.01% |
+13,720
| New | +$180K |
|
1211
Verra Mobility
VRRM
$731M
| $213K | ﹤0.01% |
+9,500
| New | +$217K |
|
1212
Woodward
WWD
$21.2B
| $212K | ﹤0.01% |
+700
| New | +$193K |
|
1213
FirstCash
FCFS
$9.14B
| $207K | ﹤0.01% |
+1,300
| New | +$205K |
|
1214
iShares MSCI India ETF
INDA
$6.58B
| $207K | ﹤0.01% |
3,829
-1,562
| -29% | -$84.2K |
|
1215
Monopar Therapeutics
MNPR
$741M
| $201K | ﹤0.01% |
+3,084
| New | +$252K |
|
1216
Hafnia
HAFN
$3.8B
| $200K | ﹤0.01% |
37,039
+2,453
| +7% | +$14.6K |
|
1217
Cabaletta Bio
CABA
$442M
| $194K | ﹤0.01% |
88,600
| – | – |
|
1218
Orchestra BioMed
OBIO
$267M
| $190K | ﹤0.01% |
45,692
-46,986
| -51% | -$190K |
|
1219
ASE Group
ASX
$103B
| $186K | ﹤0.01% |
+11,526
| New | +$164K |
|
1220
Voyager Therapeutics
VYGR
$198M
| $174K | ﹤0.01% |
44,350
| – | – |
|
|
GBIO
1221
DELISTED
Generation Bio
GBIO
| $152K | ﹤0.01% |
26,708
| – | – |
|
1222
Iovance Biotherapeutics
IOVA
$2.95B
| $146K | ﹤0.01% |
53,452
-86,426
| -62% | -$200K |
|
1223
Ginkgo Bioworks
DNA
$488M
| $108K | ﹤0.01% |
13,046
| – | – |
|
1224
Revolution Medicines Inc Warrant
RVMDW
$123M
| $38.2K | ﹤0.01% |
40,636
| – | – |
|
|
CRON
1225
Cronos Group
CRON
$1.16B
| $32K | ﹤0.01% |
12,200
| – | – |
|
Similar funds
TD Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, TD Asset Management held 1,313 positions worth $124B, up 0.95% from $123B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
TD Asset Management's Q4 2025 filing shows 78 new, 555 increased, 547 reduced and 81 closed positions. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 823,882 shares worth $80.1M. The largest sale was iShares iBoxx $ Investment Grade Corporate Bond ETF, an estimated $626M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 22% a quarter earlier, followed by Technology and Industrials.
- TD Asset Management's largest Q4 2025 buy was State Street SPDR Bloomberg High Yield Bond ETF: 823,882 shares worth $80.1M.
- TD Asset Management added most to Amphenol in Q4 2025, an estimated $281M increase.
- TD Asset Management's biggest Q4 2025 reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, cutting an estimated $626M.
- TD Asset Management fully exited Avidity Biosciences in Q4 2025, selling an estimated $19.9M.
- TD Asset Management's ten largest holdings make up 28% of its $124B portfolio in Q4 2025.
- TD Asset Management opened 78 new positions and closed 81 in Q4 2025.
- TD Asset Management's portfolio value rose 0.95% quarter-over-quarter to $124B.
Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.